I obtained a BsC in Biology in 1985 at Universidad Autónoma de Madrid. For my PhD studies, I joined Juan Ortín's lab at the CBMSO and worked on the biology of influenza virus, characterizing molecularly and functionally the viral polymerase. After getting the PhD in 1989 at UAM, I stayed in Ortín's lab at CNB until 1994 when I moved to London to the lab of Nick La Thangue at the National Institute for Medical Research. There, I worked on the G1/S transition in the mammalian cell cycle focusing in the transcription factor E2F, with fellowships from the HFSO (at NIMR) and EU-Marie Curie (at Glasgow University) Programs. In 1998, I returned to Spain with a reintegration contract to join the HSA21/Down syndrome Research group led by Xavier Estivill (IRO, Barcelona). In 2002, I joined ICREA and established my own research group working on the functional characterization of the family of kinases DYRK and their relationship with disease at the Centre for Genomic Regulation-CRG.
Protein kinases are central to all cellular processes in eukaryotes, and often linked to disease when they are altered. My group works on a family of protein kinases known as DYRK (dual-specificity tyrosine-regulated kinases), whose members -DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4- participate in the regulation of processes critical for cellular viability and homeostasis, and their dysregulation leads to disease in humans. Thus, DYRK1A overexpression in Down syndrome (DS) correlates with several DS pathological phenotypes. Moreover, mutations in one DYRK1A allele are associated with general growth retardation and microcephaly, defining a rare syndrome. DYRK1A alterations are also associated to tumor progression. My group aims at dissecting how DYRK activities are linked to human pathology. We are particularly interested on the DYRK-associated activities that impact on the regulation of expression programs either directly on chromatin or indirectly through modulation of signaling pathways.
– Luna J, Boni J, Cuatrecasas M, Bofill-De Ros X, Núñez-Manchón E, Gironella M, Vaquero EC, Arbones ML, de la Luna S* & Fillat C* 2019, ‘DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth‘, Gut, vol. 68, no. 8, pp 1465 – 1476. *, co-senior & co-corresponding authors.
– Roewenstrunk J, Di Vona C, Chen J, Borras E, Dong C, Arató K, Sabidó E, Huen MSY & de la Luna S 2019, ‘A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response“, Scientific Reports, vol. 9, no. 1, pp 6014-6028.
– Arranz J, Balducci E, Arató K, Sánchez-Elexpuru G, Najas S, Parras A, Rebollo E, Pijuan I, Erb I, Verde G, Sahun I, Barallobre MJ, Lucas JJ, Sánchez MP, de la Luna S*, Arbonés ML* 2019, ‘Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome‘, Neurobiology of Disease, vol. 127, pp 210-222. *, co-senior and co-corresponding authors.
Selected research activities
– Director of PhD thesis “DYRK1A in cancer: good or evil?. Defining properties of DYRK1A kinase as a novel tumor driver” by Jacopo Boni. Universitat Pompeu Fabra, June 2019.
– Director of PhD thesis “Exploring the role of DYRK1A in RNA polymerase III transcription: DYRK1A as a potential regulator of TFIIIC” by Rianne Cort. Universitat Pompeu Fabra, December 2019.
– New grant awarded as Principal Investigator in La Marató call on Cancer “DYRK1A inhibition to remodel tumor stroma and sensitize immune checkpoint blockade therapies in pancreatic cancer”.
– New grant awarded as Principal Investigator by the Fondation Jerome LEJEUNE “Organization of the DYRK1A interactome through docking domains: searching for novel targeting approaches”.